title: Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix.
abstract: BACKGROUND
  The activity of the combination of carboplatin and liposomal doxorubicin was tested in a Phase II study of patients with recurrent cervical carcinoma.
  
  
  METHODS
  The combination of carboplatin (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile.
  
  
  RESULTS
  Twenty-nine patients were assessable for response, and 35 patients were assessable for toxicity. The overall response rate was 38%, the median time to response was 10 weeks, the median duration of response was 26 weeks, and the median survival was 37 weeks. The main toxic effect was myelosuppression, with Grade 3 and 4 neutropenia in 16 patients, anemia in 12 patients, thrombocytopenia in 11 patients, and neutropenic fever in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal doxorubicin, leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients.
  
  
  CONCLUSIONS
  The combination of carboplatin and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma.
authors.affiliation: Multidisciplinary Center of Gynecology/Oncology, Section of Gynecologic and Medical Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. cverschr@mdanderson.org
authors.forename: C F
authors.initials: CF
authors.lastname: Verschraegen
authors.forename: J J
authors.initials: JJ
authors.lastname: Kavanagh
authors.forename: E
authors.initials: E
authors.lastname: Loyer
authors.forename: D
authors.initials: D
authors.lastname: Bodurka-Bevers
authors.forename: A P
authors.initials: AP
authors.lastname: Kudelka
authors.forename: W
authors.initials: W
authors.lastname: Hu
authors.forename: M
authors.initials: M
authors.lastname: Vincent
authors.forename: T
authors.initials: T
authors.lastname: Nelson
authors.forename: C
authors.initials: C
authors.lastname: Levenback
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008081:Liposomes; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D009503:Neutropenia / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D008081:Liposomes; D004317:Doxorubicin; D016190:Carboplatin